The U.S. Department of Energy’s National Nuclear Security Administration (NNSA) has awarded Shine Technologies $32 million to support production of molybdenum-99 (Mo-99).
The funds will aid in the ongoing construction of Chrysalis, Shine’s large-scale, medical isotope facility in Janesville, Wisconsin. Upon its completion, Chrysalis will provide a sustainable, reliable source of Mo-99 for the U.S. and satisfy more than one-third of the world’s demand, the company said.
The funding was added to NNSA’s existing cooperative agreement with Shine as part of the agency’s efforts to help establish a reliable, U.S.-produced supply of Mo-99, the most commonly used medical isotope, without the use of highly enriched uranium, the company noted.
Commercial production of Mo-99 is expected in early 2027, Shine said.
%20mol%20oct.0h6Wt2LMeF.png?crop=focalpoint&fit=crop&fp-x=0.5&fp-y=0.5&h=100&w=100&auto=format%2Ccompress&q=70)
%20mol%20oct.0h6Wt2LMeF.png?crop=focalpoint&fit=crop&fp-x=0.5&fp-y=0.5&h=167&w=250&auto=format%2Ccompress&q=70)
